Alkermes stock skidded Monday on the back of mixed results for its experimental narcolepsy treatment, an orexin agonist.

Alkermes outlined plans to move its NT1 drug candidate, alixorexton, into phase 3 after posting results from the midstage ...

Part of a class of therapies that boost “orexin” proteins, the drug just scored positive results in a Phase 2 trial. Analysts ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Alkermes plc stands fourth on our list among the most ...

Alkermes' alixorexton met key endpoints in a Phase 2 trial for narcolepsy type 1, showing strong efficacy and tolerability ...

Alkermes’ investigational drug helped people with a type of narcolepsy stay awake during the day in a mid-stage trial.

Alkermes' other CNS assets are Vivitrol, which garnered sales of $96 million in the quarter for an increase of 9% year over year, and Aristada, which logged $76 million in revenue for a 10% increase.

Ireland-based Alkermes has announced positive topline results from the randomized double-blind treatment period of the ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $40.67, a high estimate of $45.00, and a low estimate of $33.00. This upward trend is evident, with the ...

Alkermes plc (NASDAQ:ALKS) just released its annual report and things are looking bullish. It was overall a positive result, with revenues beating expectations by 3.4% to hit US$1.6b.

Alkermes (NASDAQ:ALKS) is gearing up to announce its quarterly earnings on Thursday, 2024-10-24. Here's a quick overview of what investors should know before the release.Analysts are estimating ...

Alkermes is drafting a former Major League Baseball player who has struggled with his own alcohol addiction as spokesperson for its alcohol dependency awareness campaign. ...